CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $715.9M, above the global median of $548.88M
- FinancialsAltman Z-Score 2.04: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.17BUSDvs all stocks (USD)
Revenue (TTM)
715.90MUSDvs all stocks (USD)
Profit Margin
-10.39%vs Medical Devices peers
Beta
1.57xvs all stocks
52-Week Change
119.23%vs all stocks
Market Capitalization
1.17BUSDvs all stocks (USD)
Enterprise Value
1.24BUSDvs all stocks (USD)
Forward P/E
19.97xvs Medical Devices peers
Price to Sales (TTM)
1.63xvs Medical Devices peers
Price to Book (MRQ)
1.49xvs Medical Devices peers
Enterprise to Revenue
1.74xvs Medical Devices peers
Enterprise to EBITDA
22.22xvs Medical Devices peers
Gross Margin
51.70%vs Medical Devices peers
Profit Margin
-10.39%vs Medical Devices peers
Operating Margin
5.38%vs Medical Devices peers
Return on Assets (TTM)
0.95%vs Medical Devices peers
Return on Equity (TTM)
-9.18%vs Medical Devices peers
Revenue (TTM)
715.90MUSDvs all stocks (USD)
Revenue per Share (TTM)
15.43USDUpdated Jul 18, 2026Quarterly Revenue Growth
8.80%vs Medical Devices peers
Gross Profit (TTM)
358.30MUSDvs all stocks (USD)
EBITDA (TTM)
55.40MUSDvs all stocks (USD)
Net Income (TTM)
-74.40MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-22.70%vs Medical Devices peers
Operating Cash Flow (TTM)
36.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
17.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
701.20MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
347.30MUSDFY2025 · Dec 31, 2025Gross Profit
353.90MUSDFY2025 · Dec 31, 2025Operating Income
15.40MUSDvs all stocks (USD)
Pre-tax Income
-66.20MUSDFY2025 · Dec 31, 2025Income Tax Expense
6.70MUSDFY2025 · Dec 31, 2025Net Income
-72.90MUSDFY2025 · Dec 31, 2025EBIT
-58.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
57.50MUSDFY2025 · Dec 31, 2025Research & Development
23.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
315.60MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-400.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.80MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.57USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.57USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-72.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
10.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.80MUSDFY2025 · Dec 31, 2025Income Tax Paid
14.10MUSDFY2025 · Dec 31, 2025Interest Paid
6.50MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-72.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
38.90MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
30.90MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
600.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
200.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-33.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
4.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-29.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-34.40MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-3.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-37.70MUSDFY2025 · Dec 31, 2025Shares Outstanding
46.67MSharesUpdated Jul 18, 2026Float Shares
46.03MSharesUpdated Jul 18, 2026Shares Short
1.77MSharesUpdated Jul 18, 2026Short Ratio
1.45daysvs all stocks
Short % of Shares Outstanding
4.46%vs all stocks
% Held by Insiders
3.28%vs all stocks
% Held by Institutions
92.66%vs all stocks
Total Cash (MRQ)
65.60MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.40USDUpdated Jul 18, 2026Total Debt (MRQ)
138.40MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1770xvs Medical Devices peers
Current Ratio (MRQ)
2.48xvs Medical Devices peers
Book Value per Share (MRQ)
16.76USDUpdated Jul 18, 2026Total Assets
1.07BUSDvs all stocks (USD)
Total Current Assets
355.40MUSDFY2025 · Dec 31, 2025Total Liabilities
295.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
718.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
130.30MUSDFY2025 · Dec 31, 2025Total Current Liabilities
165.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
103.70MUSDFY2025 · Dec 31, 2025Inventory
148.00MUSDFY2025 · Dec 31, 2025Accounts Payable
55.50MUSDFY2025 · Dec 31, 2025Short-term Debt
18.40MUSDFY2025 · Dec 31, 2025Long-term Debt
110.70MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
9.50MUSDFY2025 · Dec 31, 2025Common Stock (Book)
500.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-779.90MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
778.20MUSDvs all stocks (USD)
Treasury Stock
102.30MUSDFY2025 · Dec 31, 202552-Week Low
9.30USDUpdated Jul 18, 202652-Week High
25.49USDUpdated Jul 18, 202652-Week Change
119.23%vs all stocks
Beta
1.57xvs all stocks
50-Day MA
24.86USDUpdated Jul 18, 2026200-Day MA
16.45USDUpdated Jul 18, 2026Avg 10-Day Volume
575.82KSharesUpdated Jul 18, 2026Avg 30-Day Volume
894.80KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.60USDUpdated Jul 18, 2026Other Income / Expense
-77.00MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Total Assets Also Shrink
Debt has fallen for four years, and so has the asset base beside it.
Reads
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
How does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.10
Financial Health
Altman Z-Score 2.04: grey zoneSignificant
Altman Z-Score: 2.04
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $715.9M, above the global median of $548.88MNotable
Revenue (USD): 715,900,032Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novogene Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Twist Bioscience Corporation
1 interpretationDepreciation-Heavy Reported Profit